Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 9/20 | 0.45 |
| ▸ | PPARA | Q07869 | 8/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4854315 | 1.00 | NPC1 (0.50) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL4854310 | 1.00 | NPC1 (0.50) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL3369859 | 0.89 | NPC1 (0.48) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL6221868 | 0.88 | NPC1 (0.52) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL4856478 | 0.85 | NPC1 (0.53) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL3371882 | 0.85 | NPC1 (0.53) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL4856486 | 0.85 | NPC1 (0.53) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL21013647 | 0.83 | NPC1 (0.51) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL3374201 | 0.83 | NPC1 (0.51) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL4473232 | 0.82 | NPC1 (0.50) | NPC1ALDH1A1GAAPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345067-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| CN-1809541-A | Aniline derivatives | HOFFMANN LA ROCHE (CH) | 2006-07-26 | — | — | CN | disclosed |
| EP-1636198-A1 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111020-A1 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | PPARA, PPARD, PPARG | NPC1 630/4885ALDH1A1 464/4885GAA 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.